The freshness engine
What we track, and when.
Saying "constantly updated" means nothing unless you can see the process. So here it is. The sources we watch, how often, and why. Come here when something just dropped and you want to know what it actually says.
Regulatory status last checked October 12, 2026.
Daily
PubMed alerts per compound + new independent-lab batch data.
New human data and new failed-batch reports are the two things that can change a grade overnight.
Weekly
The voices below, scientists, clinicians, communicators, the fitness community, and verifiable social.
This is where claims spread before they're studied. We watch it so we can debunk or corroborate fast, and say which it is.
Monthly
Regulatory status (FDA · PCAC · Federal Register · Warning Letters) and the competitive landscape.
What's legal and compoundable changes what you can actually get. PCAC voted on BPC-157, TB-500, MOTS-c and four more on July 23-24, 2026; as of October 12, 2026 FDA has not proposed a rule, and the next tranche (GHK-Cu, LL-37 and three more) has no meeting date yet.
Every item is triaged one of three ways, update a profile, open a new one, or kill it as noise, and logged with its source and a credibility tag. So a change to a grade can always be traced back to why.
The sources we watch
28 sources watchedIndependent science
Web
Conflict-free evidence grading of compounds.
No ads, no sales, no sponsorships, the gold standard for what the evidence actually says.
Substack · @EricTopol
Cardiologist; wrote 'The Peptide Craze.'
A leading academic directly critiquing the hype cycle, keeps us honest about the gaps.
Web · Jonathan Jarry
Science communication; debunks biohacker claims.
Best-in-class myth-busting to separate signal from marketing.
Web · @foundmyfitness
Evidence-based aging & supplement science.
Rigorous, citation-heavy, generally product-agnostic.
Clinician
Web · @AbudBakri
Peptides, hormones, circadian; Huberman guest (2026).
Our lead authority, the animal-vs-human-gap framing the whole site rests on. We hold him to the same disclosure standard as everyone else here, and that cuts toward us: leaning hardest on one voice is itself a bias we should name.
⚑ Conflict: Sits on the Medical Commission of Enhanced, a company selling prescription peptides including topical GHK-Cu and sermorelin, compounds this site grades. Also publicly promotes ne1.study, a crowd-sourced N-of-1 research platform. Neither invalidates his framing, but this site flags every other figure's commercial ties and had none listed for the authority it relies on most.
Instagram · @koniverwellness
Charleston performance-medicine physician; the peptide doctor on Huberman's Oct 2024 episode. Full track record on our authorities page.
Candid field notes from the off-label frontier, worth tracking, but he sells nearly everything he recommends. Note: he did not 'pioneer' NAD IV therapy as the viral clips claim, clinical IV NAD predates him by decades.
⚑ Conflict: Runs a cash-pay clinic selling the peptides, NAD IVs and hormones he discusses; also sells a paid clinician certification and licenses branded protocols.
Web · @PeterAttiaMD
Longevity; did a full AMA on gray-market peptides.
Cautious and mechanism-first, a model of the nuance this page wants.
YouTube · @GillettHealth
Hormones, peptides; 'hype vs. misinformation' framing.
Dual board-certified; explicitly addresses peptide misinformation.
⚑ Conflict: Runs Gillett Health (labs/consults), minor.
Podcast
Metabolic scientist; peptides & metabolism, GLP-1 mechanism.
Academic physiologist explaining mechanism, not selling.
Communicator
@hubermanlab
Two dedicated peptide episodes (Koniver 2024, Bakri 2026).
The single biggest driver of mainstream peptide interest, what he covers becomes next week's search traffic.
@paulsaladinomd
Animal-based/carnivore health; metabolic & hormone takes.
Huge reach; not a peptide specialist, track the narrative, weigh the conflict.
⚑ Conflict: Founder of Heart & Soil supplements; sells products he promotes.
Web · @tferriss
Early peptide-curious podcaster; experimentation framing.
Cultural bellwether for biohacking topics crossing mainstream.
Community & fitness
YouTube · @moreplatesmoredates
The most technically detailed lay coverage of peptides/TRT.
Genuinely the deepest community explainer, treat claims as Grade D until corroborated.
⚑ Conflict: Co-owns Marek Health (TRT clinic) and Gorilla Mind (supplements).
YouTube · @CoachNicholasTrigili
Former IFBB Pro bodybuilder; long, experience-based peptide/TRT/GLP-1 breakdowns, retatrutide, GHK-Cu self-experiments, visceral-fat and 'get shredded' stacks.
Unusually granular field-level dosing and side-effect detail from someone who's actually run it, a good early read on what the physique world is using. Take with a grain of salt: treat claims as Grade D until corroborated.
⚑ Conflict: Sells coaching and cycle/protocol consults; videos promote specific stacks. Blog: nicholastrigili.com.
X · @peptidedaily_
High-velocity peptide aggregator ('scientific data behind peptides, zero marketing lies'); clips podcast content, Huberman and others, into daily threads.
A fast early read on which peptide claims are going viral, so we can fact-check them before they spread. Case in point: its Koniver thread (78K+ views) misnamed him 'Craig Conover' and called him the NAD-infusion 'pioneer' he isn't, which is exactly why aggregators get a grain of salt here.
⚑ Conflict: Anonymous lead-generation account funneling to a private list; repackages others' content and has misidentified its sources.
X · @peptidelist
Peptide-content account on X; threads on compounds, stacks and vendor chatter.
Another fast read on what's circulating in the peptide-curious corner of X, watched so we can corroborate or debunk before a claim travels. Take with a grain of salt: treat claims as Grade D until corroborated.
⚑ Conflict: Anonymous aggregator: we do not know who runs it or whether it has vendor ties, and social peptide aggregators have skewed toward lead-gen and vendor-adjacent accounts.
X · @drmarlonperalta
Doctor of Pharmacy turned performance/peptide coach; X + 'The Performance Edge' Substack. Peptides, PEDs, and a fundamentals-first message: nutrition, training and recovery before compounds.
A more grounded social voice than most, he openly argues you won't feel peptides' effects without the basics, a useful counterweight to stack-hype. The pharmacist credential gives more standing than bro-science, but still corroborate specific dosing claims (Grade D until confirmed).
⚑ Conflict: Sells peptide-optimization coaching and a paid newsletter funnel (Stan store, Substack); markets to a 'get shredded' audience.
@drmikeisraetel
Sport-physiology PhD; candid PED/peptide commentary.
Science-trained and blunt about what peptides do and don't do for muscle.
⚑ Conflict: Co-owns RP (programs/supplements), minor.
@cbum
Classic Physique Mr. Olympia (recently retired); recovery, TRT, and what the elite-physique world actually runs.
Enormous reach at the very front of physique performance, track what the top of the sport adopts before anyone else.
⚑ Conflict: Sells programs / supplements; promotes within the industry.
@thedorianyates
Six-time Mr. Olympia, HIT pioneer; unusually candid about PEDs, recovery and post-career health.
A historical authority, performance enhancement has run through bodybuilding for decades, and he's one of its most honest narrators.
⚑ Conflict: Sells training programs + a supplement line.
Conflicted commercial
@garybrecka
Sermorelin, CJC-1295+Ipamorelin, NAD+; aggressive promotion.
High-influence hype driver, track to know what claims we'll be asked to fact-check.
⚑ Conflict: Sells the peptides he promotes; FDA-flagged compounds; debunked by McGill OSS.
Web/IG (Marek, Peptual, etc.)
Direct-to-consumer marketing & dosing claims.
The front line of consumer messaging, a 'what's being sold and how it's framed' signal.
⚑ Conflict: Sell what they market.
Data & labs
Third-party purity/quantity testing; COA verification.
The default independent lab, the reference for 'is this vial real.'
Independent vendor testing (8,000+ tests, 225+ vendors).
Anecdote's antidote, independent, at scale. Trust agreement across two labs.
Saved searches per compound
Primary literature on every compound we grade.
The actual evidence base, alerts so we cite new human studies the day they post.
Regulatory
Advisory committee calendar
503A bulks reviews. Voted on BPC-157, TB-500, KPV, MOTS-c and three more on July 23-24, 2026; next tranche (GHK-Cu, LL-37, Dihexa, Melanotan II, PEG-MGF) before end of Feb 2027, date not set as of Oct 12, 2026.
The single most consequential venue for peptide legality, though its votes are advisory.
Search '503A bulk drug substances'
Official notices, comment windows, Category 1/2 changes.
The authoritative, dated record, comment deadlines matter.
Enforcement database
Enforcement vs. compounders making false peptide/GLP-1 claims.
Real-time 'who got flagged this month' signal, naming bad actors.
On the calendar
The regulatory votes and the trials that could actually move a grade. This is our "let's see what it says" list. Stuff we're genuinely watching.
FDA rulemaking on the six peptides PCAC backed
The July 23-24, 2026 vote is done and it was advisory only, so nothing about what is legal changed on July 24. FDA now reviews the meeting record, the votes and the public comments, then publishes proposed rules and opens those for feedback. That process can run about a year, and FDA is free to decline: it has gone against its own advisory panels before, and here it would only be agreeing with its own scientists, who recommended against all seven. Checked October 12, 2026: no proposed rule in the Federal Register through October 8, and docket FDA-2025-N-6895 closed July 22, 2026. This is the thing to watch, not the vote that already happened.
Track it ↗Second tranche to PCAC, including GHK-Cu
FDA lists five substances for an advisory meeting before the end of February 2027: LL-37, GHK-Cu, Dihexa acetate, Melanotan II and PEG-MGF. As of October 12, 2026 there is no meeting date, Federal Register notice or docket. They were NOT among the seven reviewed on July 23-24, which is a distinction most coverage of that meeting got wrong, so do not read the six favorable votes as covering these. And 'moving' is not the same as 'moving toward legal': for GHK-Cu the injectable form came off Category 2 in April 2026 after the nominators withdrew it, which is not permission to compound it, while the non-injectable form left Category 1 on April 22 and was added back on May 14, 2026.
Track it ↗GHK-Cu reclassification, and it is not the good-news version
Correction to an earlier version of this page, which called GHK-Cu 'the first restricted peptide moving back toward compoundable status.' That was wrong in the permissive direction, twice over. It is not first: a dozen peptides moved in the same April action. And the direction is not uniformly toward access: injectable GHK-Cu came off Category 2 after the nominators withdrew it, which is not permission to compound it, and the non-injectable form left Category 1 on April 22, 2026 before FDA added it back on May 14. FDA says it will consult the advisory committee before the end of February 2027, not at the July 2026 meeting.
Track it ↗Final call on GLP-1s and the 503B bulks list
FDA proposed on April 30, 2026 not to put semaglutide, tirzepatide or liraglutide on the 503B bulks list, which would end large-scale outsourcing-facility compounding of them from bulk powder. The comment period was extended once and closed July 30, 2026. As of October 12, 2026 there is no final decision in the Federal Register. Until there is, the proposal is a direction, not a rule.
Track it ↗MOTS-c, first human trial (Phase 2a)
The first registered human trial of MOTS-c (NCT07505745, placebo-controlled, 120 adults with prediabetes) began in February 2026 and has no results yet. When it reports, MOTS-c could leave 'animal only' for the first time.
Track it ↗BPC-157. Phase II efficacy
A registered controlled trial that, if completed, would be the first real human efficacy data for BPC-157, currently its biggest blank.
Track it ↗Retatrutide, the triple agonist
The Phase 3 readouts have landed: TRIUMPH-1 in May 2026 (28.3% average weight loss on the top dose at 80 weeks), then TRIUMPH-2 and TRIUMPH-3 on July 23, 2026. Lilly says it will submit to FDA in the first quarter of 2027. The next real event is that filing, then FDA's review; until approval it is investigational, and nothing sold under its name is Lilly's drug.
Track it ↗Tesamorelin beyond HIV
Trials extending tesamorelin's liver-fat (NAFLD/MASH) evidence beyond the HIV population it's currently approved in.
Track it ↗Recent updates
Refreshed the whole site: a currency pass on all 42 compounds.
Three GLP-1-class evidence grades (retatrutide, survodutide and cagrilintide) went up on published phase 3 trials. FDA and Federal Register status was rechecked on October 12: still no proposed rule for the July peptides, and the next panel still has no date. And we added case studies of what we actually ran, and why. No other grade moved because of a regulatory vote.
Launched the four-lens Ground Truth Score.
A single grade hid the real question. Proven for what? We split it into science, real-world signal, safety, and placebo risk so you can see exactly where the confidence lives.
Re-verified every external citation on the site.
A source you can't open isn't a source. We dropped dead links and replaced them with ones that actually resolve.
Reflected BPC-157 and TB-500 coming off FDA Category 2 (FDA's page was current as of April 22, when the nominators' withdrawals were listed).
Regulatory status changes the access picture (the legal-status lens on the profile). It never changes a grade.
See who the people behind these sources are on the authorities page, or ask us something on the questions page.